Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 26, 2021 1:39pm
171 Views
Post# 32388831

RE:RE:RE:RE:RE:Re test of last years lows?

RE:RE:RE:RE:RE:Re test of last years lows?The SP has been declining prior to the financing despite the HIV NASH(which is bigger market than HIV MDR) despite the preclinical sort1 news, despite new experience CEO, despite the announcement of the general NASH. Despite the good PR.
I guess the only thing they have learned is so far they haven't learned from past failed marketing efforts.
jeffm34 wrote: It doesn't help when you ignore the bigger more important firms to do a sweetheart deal (at the time) with your friends you still have at NB.  There were rumours when they did their prior financing that they pissed off the wrong people back then too.  I guess they don't learn. I'm curious to see the next short report. I think someone is sending a clear message to management 


<< Previous
Bullboard Posts
Next >>